## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

```
Web Page URLs for STN Seminar Schedule - N. America

Meb Rade CAS" for self-help around the clock

BEILSTEIN: Reload and Implementation of a New Subject Area

DEB Will be removed from STN

US Patent Applications available in IFICDB, IFIPAT, and IFIUDB

22 Broords from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS

23 BIOSIS Gene Names now available in TOXCENTER

Records from IP.com available in TOXCENTER

24 Rederal Research in Progress (FEDRIP) now available

New e-mail delivery for search results now available

DCTFULL has been reloaded

DCTFULL has been reloaded

COREGE no longer contains STNNDARDS file segment

Saved answer sets no longer valid

Saved answer sets no longer valid

DENAROR STREET OF SEARCHING IN REGISTRY

MEDITER TO be removed from STN

METHERT to be removed from STN
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PHARMAMARKELLETTER (PHARMAML) - new on STN
TITS has been reloaded and enhanced
Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
IFICDB, and IFIUDB have been reloaded
Sequence scarching in REGISTRY enhanced
JAPIO has been reloaded and enhanced
                                                                                                                  Welcome to STN International * * * * * * * *
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0d ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
STN Operating Hours Plus Help Desk Availability
General Internet Information
Welcome Banner and News Items
Welcome Dainer and Pelecommunication Network Access to STN
CAS World Wide Web Site (general information)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                CANCERLIT reload
                                                         TERMINAL (ENTER 1, 2, 3, OR ?):2
LOGINID: ssspta1642cxy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Aug 19
Aug 19
Aug 26
Sep 03
                                                                                                                                                                           Apr 08
Apr 09
Apr 09
Apr 19
Apr 22
Apr 22
Apr 22
Jun 10
Jun 10
Jun 10
                                                                                                                                                                                                                                                                                                                                                                                                               29
30
08
08
19
                                                                                                                                                                                                                                                                                                                                                                                                                     Jul
Jul
Aug
Aug
Aug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NEWS EXPRESS
                                                                                                                                                                                                                                                                                                                                                                                                                     NEWS 14
NEWS 15
NEWS 16
NEWS 17
NEWS 18
NEWS 19
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      20
21
22
23
                                                                                                                                                                                                                                                                                                                                                  1221
                                                                                                                                                                                                                              NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
NEWS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NEWS
NEWS
NEWS
```

Enter NEWS followed by the item number or name to see news on that specific topic.

NEWS HOURS NEWS INTER NEWS LOGIN NEWS PHONE NEWS WWW

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002

			* * * * * * * * * * * * *	* * * * * * * *		
TOTAL SESSION 0.21		(20020910/PD) 20020910/PD) 2002	the d in inal inal trion ATFULL TEW,	er es, from		
SINCE FILE ENTRY 0.21	AT 07:32:03 ON 11 SEP 2002 2002 AMERICAN CHEMICAL SOCIETY (ACS)	CATION DATE: 10 Sep 2002 20020910/ED) 1S6449768 10 Sep 2002 (20020911/UPCA NT THROUGH: 10 Sep 2002 (NT THESAURUS ISSUE DATE: Jun THESAURUS ISSUE DATE: Jun	PATFULL contains full text of published granted patents or mas full text of the latest US 101, for the inventions covered and contains not only the origin an list of any subsequent on number, patent kind code, a US publications for an inventient Information) field of USPA in standard search fields, e.g.	sed and searched togeth Type FILE USPATALL to such as patent assigne may potentially change ation. s for easy and accurate	70 (EINS) 1 70 PROTEIN(W) 70)	
=> file uspatfull COST IN U.S. DOLLARS FULL ESTIMATED COST	FILE 'USPATFULL' ENTERED AT CA INDEXING COPYRIGHT (C) 20	FILE COVERS 1971 TO PATENT PUBLI FILE LAST UPDATED: 10 Sep 2002 ( HIGHEST GRANTED PATENT NUMBER: U HIGHEST APPLICATION PUBLICATION CA INDEXING IS CURRENT THROUGH I ISSUE CLASS FIELDS (INCL) CURRE REVISED CLASS FIELDS (INCL) LAST USPTO MANUAL OF CLASSIFICATIONS	>>> USPAT2 is now available. USPATS or original, i.e., the earliest possible applications. USPAT2 contains >>> publications, starting in 2001, >>> publications, starting in 2001, >>> published document but also a  >>> publications. The publication >>> publication date for all the US >>> are displayed in the PI (Patent >>> records and may be searched in >>>  PK, etc.	>>> USPATFULL and USPAT2 can be acces >>> through the new cluster USPATALL. >>> enter this cluster. >>> Use USPATALL when searching terms >>> classifications, or claims, that is the earliest to the latest public. This file contains CAS Registry Number	s hsp70 or h 770260 770260 131043 24872 143087 113760 113809 138809 138809 138809 138809	<pre>=&gt; s 11 and adjuvant 30044 ADJUVANT 37879 ADJUVANTS</pre>

\*\*\*\*

54394 ADJUVANT

(ADJUVANT OR ADJUVANTS) 340 L1 AND ADJUVANT => dup rem 12 PROCESSING COMPLETED FOR L2 L3 340 DUP REM L2 (0 DUPLICATES REMOVED)

в 13 not py=>1999 340 S L3 7.7

816008 PY=>1999 46 L4 NOT PY=>1999

d 15 1-10 ab ٨

Ľ,

S E

ANSWER 1 OF 46 USPATFULL.

A Protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogenic and/or chemotactic activity for various cell types, particularly connective tissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions or even further may be used as an additive to cell culture media for the purpose of stimularing cell growth. The protein has a molecular weight of about 7000 daltons determined by SDS gel electrophoresis and is about 61 amino acids in length.

g P

ANSWER 2 OF 46 USPATFULL Disclosed is a Drosophila grim gene and encoded GRIM polypeptide, an arctivator of apoptosis. The disclosed nucleic acid sequences are useful in the production of the protein and as hybridization probes and primers. Expression of the GRIM protein causes programmed cell death. Preferred embodiments include expression of grim under the control of an inducible promoter and the use of such a construct in the control of an insect population.

S E

ANSWER 3 OF 46 USPATFULL.

Disclosed is a method for determining whether a test protein is capable of interacting with a nuclear hormone receptor protein. The method involves: (a) providing a horse cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including a nuclear hormone receptor protein covalently bonded to a binding modely which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein including the test protein covalently bonded to a weak gene activating modely; and (b) determining whether the test protein increases expression of the reporter gene as an independent of its ability to interact with the nuclear hormone receptor protein. Such an interaction may be hormone dependent, hormone encotion independent, or hormone receptor—independent, normone receptor—increases and the process.

ANSWER 4 OF 46 USPATFULL 5 2

The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in

ANSWER 5 OF 46 USPATFULL 5

The present invention relates to the use of a group of propargylamines of the general formula (1) ##STR1## wherein R.sup.1 is hydrogen or CH.sub.3 and R.sup.2 is (CH.sub.2).subn CH.sub.3 and is an integer from 0 to 16, and salts thereof, as callular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula i are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

ΑB

USPATFULL ANSWER 6 OF 46 P P

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention complates administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens[immunogens (i.e., with which the hsps are not complexed in vivo) or antigens[immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex as autologous to the individual. The effective amounts of the complex are in the range of nicrograms for complexes comprising hsp70, 50-1000 micrograms for complexes comprising hsp70, 50-1000 provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of Mic Class I-restricted CD8+ cytotoxic I lymphocytes complexes are also provided.

USPATFULL ANSWER 7 OF 46 P P

Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.

USPATFULL ANSWER 8 OF 46

The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR. AB AB

ANSWER 9 OF 46 USPATFULL

Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of; human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2: IFN.gamma.; IL-4; GMCSF; IL-12; B7; exb-8-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy. S E

B 5

ANSWER 10 OF 46 USPATFULL.
The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., a antigen) against which an immune response is desired, or a cytokine.

=> d 1-10 ibib

ANSWER 1 OF 46 USPATFULI 57

1998:157146 USPATFULL  DNA encoding leukocyte derived growth factor-2 (LDGF-2)  Grotendorst, Gary R., Miami, FL, United States  11da, Nacko, Miami Beach, FL, United States  University of South Florida, Tampa, FL, United States (U.S. corporation)	NUMBER KIND DATE US 5849534 19981015 US 1995-465095 Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-1177, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-1177, part of Ser. No. US 1990-472377.	filed on 1 Feb 1990, now abandoned Unility Unility Granted Kemmerer, Elizabeth C. Lahive & Cockfield, LIP, DeConti, Jr., Giulio A., Hanley, Elizabeth A. 1 24 Drawing Figure(8); 18 Drawing Page(8) 11.66 THIS PATTER	54085 sing t i, Joh Po, I rom, of Re	NUMBER KIND DATE US 5846768 19981208 US 1996-684101 19960722 (8) US 111ty CARNOIC, White & Durkee 22 1 10 Drawing Figure (s); 2 Drawing Page (s) BALE FOR THIS PATENT.	USPATFULL 1998:154029 USPATFULL NUCLEar hormone receptor-interacting polypeptides and related molecules and methods Moore, David D., Hingham, MA, United States Lee, Jae Woon, Somerville, MA, United States The General Hospital Corporation, Boston, MA, United States (U.S. corporation)	NUMBER KIND DATE US 5846711 19981208 US 1994-222719 19940404 (8)
ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:	DOCUMENT TYPE: UTilic FILE SEGMENT: UTILIC FRIMARY EXAMINER: CERMED LEGAL REPRESENTATIVE: Lahive NUMBER OF CLAIMS: 14 Hanley EXEMPLARY CLAIMS: 24 NUMBER OF DRAWINGS: 24 Dra LINE COUNTS	LS ANSWER 2 OF 46 U ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: US 5846768 APPLICATION INFO.: US 1996-684101 DOCUMENT TYPE: Utility FILE SEGMENT: Granted FRIMARY EXAMINER: Kemmerer, Elizabe LEGAL REPRESENTATIVE: Arnold, White & DI UNDRER OF CLAIMS: 1 UNDRER OF CLAIMS: 1 UNDRER OF DRAWINGS: 10 Drawing Figure LINE COUNT: 2475 CAS INDEXING IS AVAILABLE FOR THIS PATENT	LS ANSWER 3 OF 46 U ACCESSION NUMBER: TITLE: INVENTOR (S): PATENT ASSIGNEE (S):	PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: DOCUMENT TYPE:	Continuation-in-part of Ser. No. US 1992-969136, filed on 30 Oct 1992, now abandoned Utility
FILE SECHENT: PRIMARY EXAMINE: Carlson, K. LEGAL REPRESENTATIVE: Clark & Ell NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: 1 Drawing LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS	Granted Carlson, Karen Cochrane Clark & Elbing LLP 5 1 3 Drawing Figure(s); 37 Drawing Page(s) 1810 1810
L5 ANSWER 4 OF 46 t ACCESSION NUMBER: TITLE:	USPATEULL 1998:151078 USPATFULL Vertebrate embryonic pattern-inducing proteins, and
	uses related thereto Ingham, Philip W., Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S):	
	NUMBER KIND DATE
PATENT INFORMATION: APPLICATION INFO.; RELATED APPLN. INFO.:	6060 199 on-in-part of Ser
DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: ASSIGTANT EXAMINER:	1990 phen Kenneth H.
NUMBER OF CLAIMS: EXEMPLARY CLAIM:	LIP 41 1
NUMBER OF DRAWINGS: 22 LINE COUNT: 76 CAS INDEXING IS AVAILABLE	22 Drawing Figure(s); 21 Drawing Page(s) 7618 IBLE FOR THIS PATENT.
LS ANSWER 5 OF 46 L ACCESSION NUMBER: TITLE: INVENTOR(S):	USPATFULL  1998:147687 USPATFULL  Aliphatic propargylamines as cellular rescue agents  Durden, David, Saskatoon, Canada  Paterson, Alick, Saskatoon, Canada  Davis, Bruce, Saskatoon, Canada  Dvck, Lillian, Saskatoon, Canada
PATENT ASSIGNEE(S):	Yu, Peter, Saskatoon, Canada Li, Xinmin, Saskatoon, Canada Boulton, Alan, Saskatoon, Canada University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)
	NUMBER KIND DATE
PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:	19981 1904 19970
	Granted Burn, Brian M. Synnestvedt & Lechner 9
	1 4 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CALLO TO ACCULABLE FOR THIS PAIDNE.	SWER 6 OF 46 USPATFULL.  ON NUMBER: 1998:14361 USPATFULL.  Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases srivastava, Pramod K., Riverdale, NY, United States ASSIGNEE(S): Forcham University, Bronx, NY, United States (U.S. corporation)	NUMBER KIND	US 5837251 19 US 1995-527391 19 Utility Cranted Feisee, Lila Bansal, Gee Tha D. Fennie & Edmonds LLP 33 1,8,16 18 Drawing Figure(s); 8 Dr 2361 LABLE FOR THIS PATENT.	SWER 7 OF 46 USPATFULL  NUMBER: 1998:1138855 USPATFULL  NECHOGS and compositions for treating cystic fibrosis  Cheng, Seng Hing, Wellesley, MA, United States  Jáng, Canwen, Marlborco, MA, United States  ASSIGNEE(S): Genzyme Corporation, Framingham, MA, United States  (U.S. corporation)	PATENT INFORMATION:  US 534421  US 1997-807398  DOCUMENT TYPE:  US 1997-807398  US 1997-807-807398  US 1997-807-807398  US 1997-807-807398  US 1997-807-8074  US 1997-807-8074  US 1997-807-8074  US 1997-807-807-807-807-807-807-807-807-807-80
CT DWITTER CU	LS ANSWER 6 OF 4 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S)		PATENT INFORMATION: APPLICATION INFO: DOCUMENT TYPE: FILE SEGMENT: FILES SEGMENT: REMAINER: LEGAL REPRESENTATIVE LEGAL REPRESENTATIVE KYMMER OF CLAIMS: KYMMER OF CLAIMS: LINDER OF DRAWINGS: LINE COUNT: CAS INDEXING IS AVAI	L5 ANSWER 7 OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: NUMBER OF CLAIMS: NUMBER OF CLAIMS: LINE COUNT: CAS INDEXING IS AVA LS ANSWER 8 OF 46 ACCESSION NUMBER: TITLE: INVENTOR (S): PATENT ASSIGNEE (S): PATENT INFORMATION: PATENT INFORMATION: DOCUMENT TYPE: FILE SECHENT: PRIMARY EXAMINER:

```
US 583397

US 1994-18409

Continuation-in-part of Ser. No. US 1993-7115, filled on 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-7115, filled on Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filled on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filled on 7 Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1991-68567, filled on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-68567, filled on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-68567, filled on 3 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-64797, filed on 3 Mar 1990-47819, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-120471, filed on 8 Mar 1989, now Utility Cranted Crouch, Deborah

Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J.
                                                                                                                                                                                                                                                                                  Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence Paoletti, Enzo, Delmar, NY, United States Tartaglia, James, Schenectady, NY, United States Cox, William I., Troy, NY, United States Virogenetics Corporation, Troy, NY, United States corporation)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1998:134636 USPATFULL
Recombinant mycobacterial vaccines
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
Histehead Institute for Blomedical Research, United
States (U.S. corporation)
Romeo, David S.
Mohan-Peterson, Sheela, Billings, Lucy J.Incyte
Pharmaceuticals, Inc.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       46 Drawing Figure(s); 33 Drawing Page(s)
                                                                                                                             3 Drawing Figure(s); 3 Drawing Page(s)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 8
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     19981103
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              DATE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          DATE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              KIND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          KIND
                                                                                                                                                                                                                                  USPATFULL
1998:138427 USPATFULL
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Figure(tLINE COUNT: 8834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                                                          NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:
3

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   US 5830475
US 1995-460981
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NUMBER
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NUMBER
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            USPATFULL
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   DOCUMENT TYPE:
FILE SEGMENT:
PRIMARY EXAMINER:
LEGAL REPRESENTATIVE:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         L5 ANSWER 10 OF 46
ACCESSION NUMBER:
                                                                                                                                                                                                                            LS ANSWER 9 OF 46
ACCESSION NUMBER:
TITLE:
                                                                                                                                                                                                                                                                                                                                                                                                                PATENT ASSIGNEE(S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     PATENT INFORMATION:
APPLICATION INFO.:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PATENT ASSIGNEE(S):
                                                                                                                                                                                                                                                                                                                                      INVENTOR (S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   INVENTOR (S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               TITLE:
```

Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-111334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1999-367894, filed on 19 Jun 1989, now abandoned, said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 5980-336194, filed on 2 Jul 1989, now patented, Pat. No. US 59800 which is a continuation-in-part of Ser. No. US 1988-221089, filed on 2 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-16390, filed on 7 Jul 1988, now abandoned, said Ser. No. US 221089 which is a continuation-in-part of Ser. No. US 1988-6546, filed on 3 Mar 1988, now abandoned, said Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned. Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. Granted FILE SEGMENT:
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
INUMBER OF DRAWINGS:
LINE COUNT: RELATED APPLN. INFO.:

## d 1-10 ibib ab

20 Drawing Figure(s); 10 Drawing Page(s) 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT

A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogenic and/or chemotactic activity for various cell types, particularly connective tissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions, or even further may be used as an additive to cell culture media for the 1998:157146 USPATFULL
DNA encoding leukocyte derived growth factor-2 (LDGF-2)
Grotendorst, Gary R., Miami, FL, United States
Iida, Naoko, Miami Beach, FL, United States
University of South Florida, Tampa, FL, United States
(U.S. corporation) US 5849534

US 1995-465095

US 1995-665095

Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1994-1777, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-472377, Utility Kemmerer, Elizabeth C. Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Hanley, Elizabeth A. 24 Drawing Figure(s); 18 Drawing Page(s) DATE KIND EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 24 Drawing Figure (...
LINE COUNT: 1666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein, Leukocyte Derived Growth NUMBER Granted USPATFULL PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: L5 ANSWER 1 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): NUMBER OF CLAIMS: DOCUMENT TYPE: INVENTOR (S):

purpose of stimulating cell growth. The protein has a molecular weight of about 7000 dailons determined by SDS gel electrophoresis and is about 61 amino acids in length.

ACCESSION NUMBER: 1998:154085 USPATFULL ACCESSION NUMBER: 1998:154085 USPATFULL TITLE: Invertebrate apoptocats gene 'GRIM' and methods of producing the protein encoded thereby Abrams, John M., Dallas, TX, United States (Chen. Po. Dallas, TX, United States Nordstrom, William, Dallas, TX, United States Nordstrom, William, Dallas, TX, United States Nordstrom, William, TX, United States Abrams, Austin, TX, United States	NUMBER KIND DATE	LS ANSWER 3 OF 46 USPATFULL ACCESSION NUMBER: NICHAEL CONTROLLE MINISTER CONTROLLE MINIST
KIND		

c

ACCESSION NUMBER: TITLE: INVENTOR(S):	1998:154029 USPATFULL Nuclear hormone receptor-interacting polypeptides and related molecules and methods Moore. David D. Hincham. MA. United States
PATENT ASSIGNEE(S):	Lee, Jae Woon, Somerville, MA, United States The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
	NUMBER KIND DATE
PATENT INFORMATION: APPLICATION INFO.:	US 5846711 19981208 US 1994-222719 19940404 (8)
RELATED APPLN. INFO.:	n-part of Ser. No. 1
DOCUMENT TYPE: FILE SEGMENT:	Utility Granted
PRIMARY EXAMINER: LEGAL REPRESENTATIVE:	Carlson, Karen Cochrane Clark & Elbing LLP
NUMBER OF CLAIMS: EXEMPLARY CLAIM:	S □
NUMBER OF DRAWINGS: LINE COUNT:	39 Drawing Figure(s); 37 Drawing Page(s) 1810
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Disclosed is a method for determini	EXING IS AVAILABLE FOR THIS PATENT. Disclosed is a method for determining whether a test protein is capable
of interacting involves: (a) pi operably linked which expresses	of interacting with a nuclear hormone receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein blinding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein

including a nuclear hormone receptor protein covalently bonded to a binding modety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a weak gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the nuclear hormone receptor independent, or hormone sensitive. Also disclosed is purified DNA encoding thyroid hormone receptor-interacting proteins and the polypeptides expressed from such DNA.

Walsh, Stephen Sorensen, Kenneth H. Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP 41 US 5844079 19981201 US 1994-356060 19941214 (8)
Continuation-in-part of Ser. No. US 1993-176427, filed on 30 Dec 1993
Chility
Granted Vertebrate embryonic pattern-inducing proteins, and uses related thereto inflama, Philip W. Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States MA, United States (U.S. corporation) DATE NUMBER USPATFULL FILE SECHENT:
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LS ANSWER 4 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE(S): NUMBER OF CLAIMS: DOCUMENT TYPE: INVENTOR (S):

vitro and in vivo.

Aliphatic propargylamines as cellular rescue agents
Aliphatic propargylamines as cellular rescue agents
Durden, David, Saskatoon, Canada
Paterson, Alick, Saskatoon, Canada
Davis, Bruce, Saskatoon, Canada
Dovk, Lillian, Saskatoon, Canada
Yu, Peter, Saskatoon, Canada
Li, Xinmin, Saskatoon, Canada
Boulton, Alan, Saskatoon, Canada
University of Saskatchewan, Saskatoon, Canada
University of Saskatchewan, Saskatoon, Canada
University of Saskatchewan, Saskatoon, Canada LS ANSWER 5 OF 46 USPATFULL ACCESSION NUMBER: 1998:1 PATENT ASSIGNEE(S) INVENTOR(S):

19981124 DATE KIND US 5840979 PATENT INFORMATION:

1998:138855 USPATFULL

ANSWER 7 OF 46 USPATFULL

LS ANSWER 7 OF 4
ACCESSION NUMBER:

DOCUMENT TYPE:  GRANTED  FILE SCRENT:  GRANTER:  GRANTER:  BURN, Brian M.  LEGAL REPRESENTATIVE:  Synnestvedt & Lechner  1  NUMBER OF CLAIM:  CAS INDEXING:  A Drawing Figure(s); 2 Drawing Page(s)  LINE COUNT:  CAS INDEXING:  A Drawing Figure(s); 2 Drawing Page(s)  LINE COUNT:  CAS INDEXING:  A Drawing Figure(s); 2 Drawing Page(s)  LINE COUNT:  CAS INDEXING:  A AVAILABLE FOR THIS PATENT.  AB The present invention relates to the use of a group of proparcylamines of the general formula (1) ##STRI## wherein R.sup.1 is hydrogen or CH.sub.3 and R.sup.2 is (CH.sub.2) sub. CH.sub.3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.  LS ANSWER 6 OF 46 USPATFULL  ACCESSION NUMBER:  LTTIP:  LTTIP:	proteins and antigenic molecules for the treatment and prevention of neoplastic diseases  INVENTOR(S): Stivastava, Pramod K., Riverdale, NY, United States  PATENT ASSIGNEE(S): Fordham University, Bronx, NY, United States (U.S. corporation)  NUMBER KIND DATE	PATENT INFORMATION: US 5837251   19981117     APPLICATION INFO:: US 1995-527391   19950913 (8)     DOCUMENT TYPE:: Utility   Granter     FILE SEGMENT: Granter   Feisee, Lila     ASSISTANT EXAMINER: Feisee, Lila     ASSISTANT EXAMINER: Pennie & Edmonds LLP     LEGAL REPRESENTATIVE     NUMBER OF CLAIMS: 3   1,8,16     NUMBER OF DEMANNS: 18	ILABI inver spone spone eopla ount ount ock p ock p rtigen vivo	effective amounts of the first for complexes comprising the for measuring tumor rejeably a human, comprising MHC Class I-restricted tumor. Methods of purifyist provided.
--	---	---	---	---

Methods and compositions for treating cystic fibrosis Cheng, Seng Hing, Wellesley, MA, United States Jiang, Canwen, Marlboro, MA, United States Genzyme Corporation, Framingham, MA, United States (U.S. corporation) Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed. 9 Drawing Figure(s); 9 Drawing Page(s) 19981110 19970227 (8) DATE KIND FILE SEGNAT: Granted
FILE SEGNAT: Granted
FRIMARY EXAMINER: Granted
ASSISTANT EXAMINER: Celsa, Bennett
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s);
LINE COUNT: 6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and commonstrice. US 5834421 US 1997-807398 Utility Granted NUMBER PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: INVENTOR (S):

USPATFULL

1998:138682 USPATFULL Polynucleotides encoding a cofactor A-like protein Hillman, Jennifer L., San Jose, CA, United States Goli, Surya K., Sunnyvale, CA, United States Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States States (U.S. corporation) LS ANSWER 8 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE (S): INVENTOR (S):

Kemmerer, Elizabeth C.
Romeo, David S.
Mohan-Peterson, Sheela, Billings, Lucy J.Incyte (8 19981110 DATE KIND US 5834239 US 1997-825782 Utility NUMBER Granted PATENT INFORMATION: APPLICATION INFO.: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE:

3 Drawing Figure(s); 3 Drawing Page(s) 1933 Pharmaceuticals, Inc LINE COUNT:
3 Drawing Figure(s LINE COUNT:
1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present function ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: NUMBER OF CLAIMS:

The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR.

1998:138427 USPATFULL USPATFULL LS ANSWER 9 OF 46 ACCESSION NUMBER:

Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence Paoletti, Enzo, Delmar, NY, United States Tarigalia, James, Schenectady, NY, United States Cox, Walliam I., Troy, NY, United States Virogenetics Corporation, Troy, NY, United States (U.S. INVENTOR (S):

US 5830475

19951103

US 1995-460981

Continuation of Ser. No. US 1993-56627, filed on 22 Jul 1993, now patented, Pat. No. US 1959-56627, filed on 22 Jul 1993, now patented, Pat. No. US 1991-71134, filed on 6 Jun 1991, now abandoned whitch is a continuation-in-part of Ser. No. US 1989-17134, filed on 19 Jun 1989, now abandoned whitch is a continuation-in-part of Ser. No. US 1989-36194, filed on 5 Jun 1989, now patented, Pat. No. US 5504005, which is a continuation-in-part of Ser. No. US 5504005, which is a continuation-in-part of Ser. No. US 1988-223089, filed on 2 Jul 1988, now abandoned And Ser. No. US 1988-213089, filed on 7 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No.

DATE

KIND

NUMBER

PATENT ASSIGNEE(S):

INVENTOR (S):

APPLICATION INFO.: RELATED APPLN. INFO.:

PATENT INFORMATION:

corporation) PATENT ASSIGNEE(S):

DATE KIND

US 5833975
US 1994-184009
US 1994-184009
US 1994-184009

1940119

20 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-7115, filled on the Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filled on I Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filled on 7 Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filled on 7 Mar 1991, now abandoned vincin a set of the Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-806605, filled on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-80600, filled on 1 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847977, filled on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478179, filled on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320411, filled on 8 Mar 1989, now patented, Pat. No. US 5155020 ILINE COUNT:

AB Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses ame bn NYAAC or ALVAC recombinant viruses are bn STAAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IR: gamma.; IL-4; GWCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy. Recombinant mycobacterial vaccines Aldovini, Anna, Winchester, MA, United States Young, Richard A., Winchester, MA, United States Hatchead Institute for Biomedical Research, United States (U.S. corporation) Granted Crouch, Deborah Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J. 46 Drawing Figure(s); 33 Drawing Page(s) 1998:134636 USPATFULL USPATFULL LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: ANSWER 10 OF 46 EXEMPLARY CLAIM: NUMBER OF DRAWINGS: NUMBER OF CLAIMS: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: ACCESSION NUMBER:

us 1988-163546, filed on 3 Mar 1988, now abandoned , said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 103546 which is a continuation-in-part abandoned US 1987-20451, filed on 2 Mar 1987, now UTILITY 20 Drawing Figure(s); 10 Drawing Page(s) Granted Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. FILE SEGMENT: Granted FRINGER SEGMENT: Granted SERIANT EXAMINER: Bliott, George C. ASSISTANT EXAMINER: Railey, II. Johnny F. LEGAL REPRESENTATIVE: Hamilton, Brook, Smit WINDER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s). LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB The present invention relates to recom

The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

=> d his

(FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002 820 S HSP70 OR HEAT SHOCK PROTEIN 70 340 S.L1 AND ADJUVANT 340 DUP REM L2 (0 DUPLICATES REMOVED) 340 S.L3 NOT PY=>1999 33233

=> d 15 10-20 ibib ab

1999:134636 USPATFULL
Recombinant mycobacterial vaccines
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
Histered Institute for Biomedical Research, United
States (U.S. corporation) DATE KIND NUMBER USPATFULL LS ANSWER 10 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): INVENTOR (S):

US 5830475
US 1995-46091
US 1995-46091
Continuation of Ser. No. US 1995-6527, filed on 22 Jul 1993. now patented, Pat. No. US 1995-6522 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991. now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned, said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 1989-36194, filed on 5 Jun 1999, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-213089, filed on 2 Jul 1988, now abandoned abandoned which is a continuation-in-part of Ser. No. US 1988-215390, filed on 7 Jul 1988, now abandoned abandoned which is a continuation-in-part of Ser. No. US 1988-16546, filed on 3 Mar 1988, now abandoned, said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 1988-16546 which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now of Ser. No of Ser. No abandoned APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention compulst disease administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. Antigenic molecule as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens fimmunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the effective amounts of the complex when administered embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising happing, 5 to 49 micrograms for known administered subodiment, the effective amounts of the complexe the effective amounts of the complexe send of 0.1 to 9.0 micrograms for complexes comprising happing are in the range of 10 to 600 micrograms for complexes comprising happing are in the range of 10 to 600 micrograms for complexes comprising happing to 60 to 600 micrograms for complexes comprising happing are in the range of 10 to 600 micrograms for complexes comprising happing to 60 to 600 micrograms for complexes comprising happing to 60 to 600 micrograms for complexes compressing for 6000 micrograms for complexes compressing for 6000 micrograms for 6000 micrograms for 6000 micrograms for 6000 micrograms for The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine. 1998:134628 USPATFULL Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive United States States (U.S. 20 Drawing Figure(s); 10 Drawing Page(s) Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. Srivastava, Pramod K., Riverdale, NY, Fordham University, Bronx, NY, United 19981103 DATE KIND Granted Saunders, David VanderVegt, F. Pierre Pennie & Edmonds LLP Pierre LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to me LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT. US 5830464 US 1997-796316 Utility immunotherapy corporation) NUMBER USPATFULL LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: 46 INVENTOR(S):
PATENT ASSIGNEE(S): PRIMARY EXAMINER: ASSISTANT EXAMINER: PATENT INFORMATION: L5 ANSWER 11 OF ACCESSION NUMBER: TITLE: APPLICATION INFO.: PRIMARY EXAMINER DOCUMENT TYPE: FILE SEGMENT:

USPATFULL 1998:131609 USPATFULL In vitro activation of cytotoxic T cells 46 L5 ANSWER 12 OF ACCESSION NUMBER: TITLE:

Peterson, Per A., La Jolla, CA, United States Jackson, Michael, Del Mar, CA, United States Langlade-Demoyen, Pierre, Del Mar, CA, United States The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation) PATENT ASSIGNEE(S)

US 5827737
US 1996-669685
US 1996-669685
19960624 (8)
Mar 1994, now patented, Pat. No. US 5529921 which is a continuation of Ser. No. US 1992-841662, filed on 19 Feb 1992, now patented, Pat. No. US 5314813
Utility
Granted 25 Drawing Figure(s); 19 Drawing Page(s) DATE Tsang, Cecila J. VanderVegt, F. Pierre Townsend & Townsend & Crew KIND NUMBER ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER:

AB TOWARD TOWARD THE TOWARD TO

USPATFULL
1988:119133 USPATFULL
PROLECTIVE 17 KDA malaria hepatic and erythrocytic stage immunogen and gene 46 LS ANSWER 13 OF ACCESSION NUMBER: INVENTOR (S):

Hoffman, Stephen L., Gaithersburg, MD, United States Charcenvit, Yupin, Silver Spring, MD, United States Hedstrom, Richard C., Gaithersburg, MD, United States Doolan, Denise L., Rockville, MD, United States The United States Secretary of the Navy, Washington, DC, United States (U.S. government) PATENT ASSIGNEE(S):

17 Drawing Figure(s); 7 Drawing Page(s) (8) 19980929 DATE KIND Cunningham, Thomas M. Spevack, A. David US 5814617 US 1994-319704 Utility Granted NUMBER 1590 FILE SEGMENT:
PRIMARY EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIMS:
UNIMBER OF DRAWINGS:
LINE COUNT: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An IqG1 monoclonal antibude.

An Igg1 monoclonal antibody, Navy Yoelii Liver Stage 3 (NYLS3) does not recognize sporozoites, but recognizes P. yoelii Liver stage parasites within 6 hours of invasion of mouse hepatocytes, and throughout the hepatic and asexual erythrocytic stages of the life cycle. When added to primary cultures of mouse hepatocytes 24 hours after incoulation with P. yoelii sporozoites, when all sporozoites have invaded hepatocytes, NYLS3

Will all minates up to 98% of liver stage parasites. Intravenous injection of NYLS3 into mice delays the onset and reduces the density of blood stage parasitemia after sporozoite or blood stage challenge. The protein recognized by this mab is identified and designated P. yoelil hepatic and erythrocytic stage protein. The game encoding PHEP17 and a DNA vaccine comprising exons of the DNA that encodes PHEP17 are disclosed. A DNA vaccine consisting of exon 1 and part of exon 2 of the gene encoding PHEP17 protects 86% of A/J mice, 33% and development of blood-stage parasitemia. A combination of DNA vaccines complete protection against development of blood-stage parasitemia. A combination of DNA vaccines complete protection against development of blood-stage parasitemia in BALB/C mice and 71% protection in A/J and BDLO.BR mice. This DNA vaccine-induced protection may be additive. Combinations of other malaria antigens are covered. The application discloses the P. Fallschum chomolog of PHEP17 and including steep parasitemia in featurements of the PHEP17 homologs of the other Plasmodium species which infect humans, specifically P. vivax, P. ovale and P. malariae.

Heat shock-like protein Hillman, Jennifer L., San Jose, CA, United States Shah, Purvi, Sunnyvale, CA, United States Thyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation) 5 Drawing Figure(s); 4 Drawing Page(s) 8 19980929 DATE KIND USPATFULL 1998:119003 USPATFULL Wax, Robert A. Bugalsky, Gabriele E. Billings, Lucy J. US 5814481 US 1997-846134 Utility NUMBER Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: 46 EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE (S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: LS ANSWER 14 OF ACCESSION NUMBER: PRIMARY EXAMINER: FILE SEGMENT: INVENTOR (S):

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING THE present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.

Inhibitors of IMPDH enzyme
Armistead, David M. Maynard, MA, United States
Badia, Michael C., Bedford, MA, United States
Bedia, Michael C., Alliston, MA, United States
Benis, Guy W., Arlington, MA, United States
Bethiel, Randy S., Alliston, MA, United States
Frank, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Matertown, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
Vertex Pharmaceuticals Incorporated, Cambridge, MA,
United States (U.S. corporation) LS ANSWER 15 OF 46 USPATFULL ACCESSION NUMBER: 1998:11 PATENT ASSIGNEE(S): INVENTOR (S):

NUMBER US 5807876 PATENT INFORMATION:

Granted Shah, Wukund J. Shah, Bruck Fish & Neave, Haley, Jr., James F., Govindaswamy, N. APPLICATION INFO:: US 1996-636361
DOCUMENT TYPE: Utility
FILE SEGNENT: Granted
FRIMARY EXAMINER: Shah; Mukund J.
ASSIGTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Fish & Neave, Haley,
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 1
LINE COUNT: 1
LINE COUNT: 1494
AB The present invention value.

The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as agents for immunosuppression. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

1998:101540 USPATFULL

Human protein disulide isomerase

Human protein disulide isomerase

Muzzy, Lynn E., Portola Valley, CA, United States

Muzzy, Lynn E., Portola Valley, CA, United States

Incyte Pharmaceuticals, Inc., Palo Alto, CA, United

States (U.S. corporation) USPATFULL LS ANSWER 16 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE (S): INVENTOR(S):

US 5798249 US 1996-650275 Lontinuation-in-part of Ser. No. US 1996-649740, filed on 15 May 1996 DATE KIND DOCUMENT TYPE:

PLIE SEGMENT:

PRIMARY EXAMINE:

ASSISTANT EXAMINE:

LEGAL REPRESENTATIVE:

RIGHAN TEXCHANS:

Saidha, Texchand

LEGAL REPRESENTATIVE:

RIGHAN TEXCHANS:

SAIMS LUCY J.

NUMBER OF CLAIMS:

REMPHARY CLAIM:

NUMBER OF DRAWINGS:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB THE present invention provides a polvy NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

13 Drawing Figure(s); 13 Drawing Page(s) 2291

The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions for treatment of diseases resulting or the complement thereof, which hybridize with the genomic sequence or the transcript of pdih, or anti-PDIH antibodies which specifically bind to the polypeptide, PDIH.

USPATFULL L5 ANSWER 17 OF 46 ACCESSION NUMBER: TITLE:

1998:92162 USPATFULL
Vertebrate embryonic pattern-inducing proteins and uses related thereto

INVENTOR(S):	Ingham, Philip W., Summertown, England MoWahon, Andrew P., Lexington, MA, United States Makin of States and Cambridges MA, United States
PATENT ASSIGNEE(S):	
	NUMBER KIND DATE
PATENT INFORMATION: APPLICATION INFO.:	543 1998080 -176427 1993123
DOCOMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER:	Ocinicy Walsh, Stephen
ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:	ense
NUMBER OF CLAIMS: EXEMPLARY CLAIM:	15. 13.5 1
NUMBER OF DRAWINGS: LINE COUNT:	12 Drawing Figure(s); 15 Drawing Page(s) 4235
CAS INDEXING IS AVAILAE AB The present inve	INDEXING IS AVAILABLE FOR THIS PATENT.  The present invention concerns the discovery that proteins encoded by a
family of ve	genes, termed here hedgehog-related genes, compri produced by embryonic patterning centers, and are
involved in the differentiated t	involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes
available composit generate and/or ma vitro and in vivo.	available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
L5 ANSWER 18 OF 46 L ACCESSION NUMBER: TITLE:	USPATFULL 1998:91811 USPATFULL Detection of wheat that has experienced elevated
INVENTOR(S): PATENT ASSIGNEE(S):	temperatures during the grain filling period Bernardin, John E., El Sobrante, CA, United States The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. corporation)
	NUMBER KIND DATE
	19980804 19951013 (8)
RELATED APPLN. INFO.:	ation of Ser. No. ow abandoned
DOCUMENT TYPE: FILE SEGMENT:	Utility Granted
PRIMARY EXAMINER: ASSISTANT EXAMINER:	Hutzell, Paula K. Grun James I.
LEGAL REPRESENTATIVE:	Silverstein, M. Howard, Fado, John D., Connor, Margaret
NUMBER OF CLAIMS: EXEMPLARY CLAIM:	7. 1.8
DRAWINGS I:	6 Drawing Figure(s); 6 Drawing Page(s) 999
AB Methods for dete experienced elev	r detecting heat-stressed wheat, that is, wheat that has it elevated temperatures during the grain filling period, and assess end-use nonnerries of wheat grain are disclosed in
method	is measured. Wheat grain or flour th
has a level of whether the constitutive temperatures duri	wheat heat stress peptide two or more times greater that relevel is determined to have experienced elevated tring the grain filling period. In the method to assess an
end-use property	end-use property of wheat, wheat heat stress peptide in a sample of

wheat grain or flour is measured, and the level is compared to a calibration curve that correlates the level of wheat heat stress peptide and the end-use property.	ACCESSION NUMBER: 1908 46 USPATFULL THOUSESTON NUMBER: 1908: 88652 USPATFULL THOUSESTON NUMBER: Therapeutic and diagnostic methods and compositions Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids Artavanis-TSakonas, Spyridon, Hamden, CT, United States Fehon, Richard Grant, Durham, NC, United States Zagouraa, Panayiotis, New Haven, CT, United States Blaumueller, Christine Marie, New Haven, CT, United States S	COTPORATION)  NUMBER KIND DATE  PATENT INFORMATION: US 5786158  APPLICATION INFO.: US 1993-83590  RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-955012, filed on 30 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-879038, filed	DOCUMENT TYPE:  On 30 Apr 1992, now abandoned  DOCUMENT TYPE:  Utility  FILE SEGMENT:  Granted  CARLANS:  Scheiner, Toni R.  LEGAL REPRESENTATIVE:  Pennie & Edmonds LLP  NUMBER OF CLAIMS:  SEXEMPLARY CAAIM:  10 Drawing Figure(s); 68 Drawing Page(s)  EXEMPLARY CAAIM:  AS THE PRESENTATIVE:  AS THE PRESENTATIV	ACCESSION NUMBER: 1998:82345 USPATFULL ACCESSION NUMBER: 1998:82345 USPATFULL TITLE: Diagnosis and treatment of insulin dependent diabetes Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents CODEN, Irun R., Rehovot, Israel Elias, Dana, Rehovot, Israel Markovits, Doron, Rehovot, Israel Markovits, Doron, Rehovot, Israel APTENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)	NUMBER KIND DATE  PATENT INFORMATION: US 5780034  APPLICATION INFO.: US 1959-384454  RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-937449, filed on 31  Aug 1992, now abandoned which is a continuation of Ser. No. US 1990-493127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-493127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-371449, filed on 26 Jun 1989, now patented, Pat. No. US 19444 which is a continuation-in-part of Ser. No. US 514444 which is a continuation-in-part of Ser.	No. US 1989-122864, filed on 14 Mar 1989, now abandoned Unility FILE SEGMENT: Granted Cunningham, Thomas M. LEGAL REPRESENTATIVE: Browdy and Neimark NUMBER OF CLAIMS: 18
---	--	---	--	---	--	---

US 5780034
US 1995-34444
US 1995-344454
US 1995-344454
Continuation of Ser. No. US 1992-937449, filed on 31
Aug 1992, now abandoned which is a continuation of Ser.
No. US 1990-493127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-331249, filed on 26 Jun 1989, now parented, Pat.
No. US 5114844 which is a continuation-in-part of Ser.
No. US 1989-322864, filed on 14 Mar 1989, now abandoned Utility
Granted
Cunningham, Thomas M.
Browdy and Neimark A 65 KD heat shock protein, proteins cross-reactive therewith, and both both so and thookes therefor or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hisp65 can be used to detect the hisp65 molecule in blood or urine. The hisp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, of clinical symptoms thereof. I cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of Diagnosis and treatment of insulin dependent diabetes melitus using heat shock protein determinents Cohen, Irun R., Rehovot, Israel Blias, Dana, Rehovot, Israel Markovitus, Dozon, Rehovot, Israel Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation) 8 Drawing Figure(s); 6 Drawing Page(s) DATE KIND USPATFULL 1998:82345 USPATFULL PRIMARY EXAMINER: Cunningham, Thomas M LEGAL REPRESENTATIVE: Browdy and Neimark NUMBER OF CLAIMS: 18 EXWEPLARY CLAIM: 1 NUMBER OF DRAWINGS: 8 Drawing Figure(8); LINR COUNT: 1667
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB A 65 KD heat shock proteins ( NUMBER PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: L5 ANSWER 20 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): => d 20-30 ibib ab DOCUMENT TYPE: INVENTOR (S):

46 USPATFULL 1998:78722 USPATFULL Recombinant mycobacterial vaccines

LS ANSWER 21 OF ACCESSION NUMBER: TITLE:

PRIMES EXAMINE: Granted PRIMARY EXAMINER: Mosher, Mary E. IEGAL REPRESENTATIVE: Foley & Lardner NUMBER OF CLAIMS: 19 EXEMPLARY CLAIM: 10 EXEMPLARY CLAIM: 126 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB Defective poxylituses that lack a function imparted by an essential AB Cefective poxylituses that lack a function imparted by an essential AB Cefective poxylitus are provided for protein production and vaccination. A DNA polymucleotide encoding a protein is inserted into the defective poxylitus and placed under transcriptional control of a promoter. The defective poxylitus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or	LS ANSWER 23 OF 46 USPATFULL ACCESSION NUMBER: recombinant poxviruses with foreign DNA in essential regions INVENTOR(S): Falkner's Falke-Gunter, Vienna, Austria Holzer, Georg, Vienna, Austria Domner, Friedfich, Vienna, Austria Domner, Friedfich, Vienna, Austria corporation)  PATENT ASSIGNEE(S): corporation)
ANSWER 23 OF 46 USPATFULL ESSION NUMBER: 1998:68807 USPATFULL TIE: recombinant poxviruses with foreign DNA in regions FEBLOR(S): FEBLOR'S Falko-Gunter, Vienna, Austria Holzer, Georg, Vienna, Austria Holzer, Eriediich, Vienna, Austria Immuno Aktiengesellschaft, Vienna, Austria corporation)	
ANSWER 23 OF 46 USPATFULL ESSION NUMBER: recombinant poxviruses with foreign DNA in essential regions FEMTOR(S): regions FEMTOR (S): Falkner, Falko-Gunter, Vienna, Austria Borner, Falko-Gunter, Vienna, Austria Borner, Falko-Gunter, Vienna, Austria Corporation)  NUMBER (S): Corporation)  NUMBER (S): S766882  EENT INFORMATION: US 5766882  US 5766882  US 5766882  US 5766882  US 5766882  US 1996-616133  ANDER (S): 1996014 (8)  Continuation-in-part of Ser. No. US 1994-235392, fi Cangell, Bruce R.  ES EGMENT: Cangell, Bruce R.  AL REPRESENTATIVE: Gampell, Bruce R.  SAL REPRESENTATIVE: Foley & Lardner Cangell, Bruce R.  SHER OF CLAIMS: Brawing Figure(S): 8 Drawing Page(S)  SINDEXING IS AVAILABLE FOR THIS PATENT.  Defective poxvituese that lack a function imparted by an essential Defective poxvitues are provided for protein production region of its parental poxvitues are provided for protein production	KIND DATE
ANSWER 23 OF 46 USPATFULL  ESSION NUMBER:  TECOMDINANT PAIRCALL  TENT ASSIGNEE(S):  FALKER FEAR TOTALL  TENT ASSIGNEE(S):  FALKER FEAR TOTALL  TENT ASSIGNEE(S):  FALKER FEAR TOTALL  TOTAL TOTAL TOTAL  NUMBER  TOTAL TOTAL  TOTAL  TOTAL TOTAL  T	NUMBER KIND DATE  10 S 5766882 19980616  10 S 1996-616133 19980618  10 129 Apr 1994, now abandoned  Unilty Granted Campell, Bruce R.  11 S: 8 Drawing Figure(8); 8 Drawing Page(8)  1322  1322  NAILABLE POR THIS PATENT.  POWYINUSE that lack a function imparted by an essential powyirus are provided for protein production and placed under transcriptional control of a The defective powyirus is viable when the lost function of region is complemented by a host cell, transgenic animal or us.  46 USPATFULL  46 USPATFULL  67 STATES  1988:57767 USPATFULL  CELL STATES TRANSCRIPTIONAL CELL STATES  CLOS TRANSCRIPTIONAL CONTROL OF A THE BEFFERDAL TRANSCRIPTIONAL CELL STREES TRANSCRIPTIONAL CELL STREES TRANSCRIPTIONAL CELL STREES TRANSCRIPTIONAL CELL STREES CLOSE AND United STREES

Division of Ser. No. US 1990-617910, filed on 26 1990, now abandoned 44 Drawing Figure(s); 28 Drawing Page(s) Low, Christopher S. F. Morgan & Finnegan, L.L.P. LEGAL REPRESENTATIVE: Morgan & Finnegan, NUMBER OF CLAIMS: 15 EXEMPLARY CLAIMS: 1 NUMBER OF DARWINGS: 44 Drawing Figure (LINE COUNT: 1762
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB The present invention relates to DN 1990, nc Utility RELATED APPLN. INFO.: PRIMARY EXAMINER:

The present invention relates to DNA sequence coding for part or all of the heat shock transcription factor or heat shock factor (HSF) proteins derived from humans and Drosophila, and the proteins encoded by these sednences.

The present invention also includes methods for detecting HSF in a biological sample. The presence of HSF in the nucleus of a cell can be detected with specific anti-HSF antibody reagents. The presence of such HSF proteins in the nucleus indicates a stressed condition including diseases. Furthermore, the presence of multimeric HSF in the crude or fractionated cell extract is indicative of a stressed state.

Deltex proteins

Artavanis-Taeakonas, Spyridon, Hamden, CT, United States
Busseau, Isabelle, Bures-Sur-Yvette, France
Diederich, Robert J., New Haven, CT, United States
Matsuno, Kenji, New Haven, CT, United States
Yale University, New Haven, CT, United States
Yale University, New Haven, CT, United States USPATFULL 1998:51728 USPATFULL L5 ANSWER 25 OF 46 ACCESSION NUMBER: INVENTOR (S):

corporation) PATENT ASSIGNEE(S):

DATE KIND NUMBER

58 Drawing Figure(s); 40 Drawing Page(s) (8) 19980512 19940121 FILE SEGNENT: Granted
ARIMANY EXAMINER: Walsh, Stephen
ASSISTAMT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
WUMBER OF CLAIMS: 1
NUMBER OF DRAWINGS: 58 Drawing Figure(s);
LINE COUNT: 4194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to amino Walsh, Stephen Sorensen, Kenneth A. Pennie & Edmonds LLP US 5750652 US 1994-185432 Utility Granted PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

The present invention relates to amino acid sequences of the encoded deletex protein. The invention further relates to fragments and other derivatives, and analogs, of deltex proteins. In specific embodiments, the invention relates to deltex protein derivatives and analogs of the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gil-rich clusters, SH3 binding domains which mediate binding to Notch or to a Notch derivative containing Notch cdcl0/SW16/ankyrin ("ANK") repeats, domains which mediate binding to Notch or any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

USPATFULL LS ANSWER 26 OF 46 ACCESSION NUMBER: TITLE:

1998:51204 USPATFULL Immunotherapeutic stress protein-peptide complexes adainst cancer

LINE COUNT:

CAS INDEXING 1 and method for inhibiting the proliferation of a tumor in a mammal. The method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the Hsp70-peptide, Hsp90-peptide and gp96-peptide complexes. US 5750119 19980512 US 1994-315892 19940930 (8) Continuation-in-part of Ser. No. US 1994-180685, filed Utility Srivastava, Pramod K., Riverdale, NY, United States Mount Sinai School of Medicine Of The City University of New York, New York, NY, United States (U.S. DATE KIND Feisee, Lila Bansal, Geetha P. Pennie & Edmonds LLP corporation) NUMBER RELATED APPLN. INFO.: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PATENT ASSIGNEE(S): PATENT INFORMATION: INFO.: NUMBER OF CLAIMS: EXEMPLARY CLAIM: PRIMARY EXAMINER: DOCUMENT TYPE: SEGMENT: INVENTOR (S): APPLICATION

1998 48564 USPATFULL P53AS protein and antibody therefor Kulesz-Martin, Molly F., Buffalo, NY, United States Health Research, Inc., Buffalo, NY, United States (U. corporation) USPATFULL ANSWER 27 OF 46 INVENTOR(S): PATENT ASSIGNEE(S): L5 ANSWER 27 OF ACCESSION NUMBER:

US 5747650 19980505 US 1996-644456 19960510 (8) Continuation-in-part of Ser. No. US 1993-100496, filed on 2 Aug 1993 Utility DATE KIND NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

26 Drawing Figure(s); 11 Drawing Page(s) PRIMARY EXAMINE:
ASSISTANT EXAMINER:
ASSISTANT EXAMINER:
Bansal, Geetha P.
LEGAL REPRESENTATIVE:
Dunn, Michael L.
KENPELARY CLAIMS:
11
KUNBER OF DRAWINGS:
26 Drawing Figure(8);
LINE COUNT:
CAS INDEXING:
AB IN accordance with the present inventi Granted DOCUMENT TYPE: FILE SEGMENT:

In accordance with the present invention, we have discovered and purified a protein designated herein as p53as, which protein is present in normal cells of a mammal and is essentially identical to known normal growth controlling protein p53 of the same mammal, at least until the final 50 amino acids of the carboxy terminal end of the protein. The invention further includes an antibody specific for protein p53as, which antibody is designated herein as Ab p53as. The antibody may be either a monoclonal or polyclonal antibody and may be specific for p53as of any particular mammal such as mice and humans.

ANSWER 28 OF 46 USPATFULL 15

PRIORITY INFORMATION: CA 1990-2027434 19901012

FILE SEGMENT TYPE: Grante Grante FILE SEGMENT: Grante Wolski, Susan LEGAL REPRESENTATIVE: Wolski, Susan LEGAL REPRESENTATIVE: Nauber & Jackson NUMBER OF CLAIM: 13

EXEMPLARY CLAIM: 13

EXEMPLA 46 USPATFULL

1998:36577 USPATFULL

Vectors and prokaryotes which autocatalytically delete antiblocic resistance
Haun, Shirley L., Galthersburg, MD, United States
Stover, Charles K., Mercer Island, WA, United States
Hatfull, Graham, Pittsburgh, PA, United States
Hanson, Mark S., Columbia, MD, United States
Jacobs, William R., City Island, NY, United States
Jacobs, William R., City Island, NY, United States
Corporation) US 574458 19980428 19980428 19960905 (8) Continuation of Ser. No. US 1995-420298, filed on 11 Apr 1995, now patented, Par. No. US 5604105 which is a continuation-in-part of Ser. No. US 1993-26453, filed on 1 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-695381, filed on 3 May 1991, now patented, Pat. No. US 5290678, US 5736367
US 1995-425380
US 1995-425380
US 1995-425380
19950420 (8)
Continuation-in-part of Ser. No. US 1992-861002, filed on 31 Mar 1992
Utility
Cranted
Cranted
Fleisher, Mindy
Weiss, Bonnie D.
Herron, Charles J., Olstein, Elliot M. 1998:45097 USPATFULL
Method and device for diagnosing and distinguishing
chest pain in early onset thereof
Jackowski, George Inglewood, Canada
Spectral Diagnostics Inc., Toronto, Canada (non-U.S.
Corporation) DATE KIND DATE 19901012 DATE KIND NUMBER NUMBER NUMBER DOCUMENT TYPE: FILE SEGNENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LS ANSWER 29 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE(S): PATENT ASSIGNEE(S): ACCESSION NUMBER: INVENTOR (S): INVENTOR (S):

EXEMPLARY CLAIMS:  1	NUMBER KIND DATE  PATENT INFORMATION: US 1935-379613 19950222 (8)  MO 9403-1087096 1995022 (8)  MO 1993-US7096 1995022 PCT 102(e) date  NUMBER DATE	PRIORITY INFORMATION: Utility Granted Utility Granted Growth TYPE: Pennie & Edmonds 15 The STANTIAR: 25 The STANTIAR: 25 The STANTIAR: 49 Drawing Figure(s); 19 Drawing Page(s) 1401 CAS INDEXING: 49 Drawing Figure(s); 19 Drawing Page(s) LINE COUNT: The Invention relates to conjugates of poorly immunogenic antigens, e.g. The Invention relates to conjugates of the sequence of human heat constituting a T cell epitope derived from the sequence of human heat should capable of increasing substantially thereof, said epitide or analog being capable of increasing substantially the immunogenic in Stitable peptides according to the invention are Pep278h, which corresponds to positions 437-448 of human hsp65, and Pep II, which corresponds to positions 442 and 447 are replaced serine residues.	L5 ANSWER 30 OF 46 USPATFULL ACCESSION NUMBER: 1998:36365 USPATFULL TITLE: Conjugates of poorly immunogenic antigens and synthetic populates and vaccines comprising them peptide arxiers and vaccines comprising them Cohen, Irun R., Rehovot, Israel Fridkin, Matityahu, Rehovot, Israel
----------------------	---	---	--

PCT 371 date PCT 102(e) date Konen-Waisman, Stephanie, Tel Aviv, Israel Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation) 19950222 19980407 19940217 19930728 DATE 19920730 DATE KIND ď Woodward, Michael Pennie & Edmonds US 5736146 WO 9403208 US 1995-379613 WO 1993-US7096 IL 1992-102687 Utility NUMBER NUMBER PRIORITY INFORMATION: DOCUMENT TYPE: PATENT ASSIGNEE (S): PATENT INFORMATION: APPLICATION INFO.: FILE SEGMENT: PRIMARY EXAMINER:

49 Drawing Figure(s); 19 Drawing Page(s) 

The invention relates to conjugates of poorly immunogenic antigens, e.g. epptides, proteins and polysaccharides, with a synthetric peptide carrier constituting a T cell epitope derived from the sequence of human haat shock protein hsp65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are pep278h, which corresponds to positions 458-474 of human hsp65, and Peptwo, systeine residues at positions 442 and 447 are replaced serine

Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53) van den Hurk, Jan, Saskatoon, Canada Tijseen, Peter, Pointe Claire, Canada Biostar Inc., Saskatoon, Canada (non-U.S. corporation) 46 USPATFULL 1998:6790 USPATFULL L5 ANSWER 31 OF ACCESSION NUMBER: TITLE: INVENTOR (S):

865 19980120 DATE KIND NUMBER

corporation)

PATENT ASSIGNEE(S):

US 5709865 US 1995-445746 19950522 (8) Continuation-in-part of Ser. No. US 1994-337618, filed On 10 Nov 1994, now abandoned Utility Knode, Marian C. Salimi, Ali R. Sholtz, Charles K.Dehlinger & Associates 13 Drawing Figure(s); 12 Drawing Page(s) Granted PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE;
NUMBER OF CLAIMS:
EXEMPLARY CLAIM;
NUMBER OF DRAWINGS; PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: DOCUMENT TYPE:

LINE COUNT:

1881

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB. This invention relates to the identification of Bovine Viral Diarrhea Virus group II (BVD-II) nucleic acid sequences (e.g., gp53 sequences) to methods of using the nucleic acid sequences for detecting BVD-II virus in animal sera, to polypeptide vital antigens derived from the

sequences and immunoreactive with sera from animals infected with Bovine Viral Datraftea group II (BVD-II) virus, to polynucleoride sequences which encode these polypeptide antigens, to an expression system capable of producing the polypeptide antigens, to vaccines containing the polypeptide antigens, to using the polypeptide antigens, to methods of using the polypeptide antigens for detecting BVD-II virus antibodies in animal sera, and to antibodies directed against these polypeptide antigens.

US 5705359
US 1955-434055
US 1957-434055
US 1958-434055
US 1958-434055
US 1958-434055
US 1958-43405
US 1958-43405
US 1958-43405
US 1958-43405
US 1958-43405
US 1950, now abandoned And a continuation in-part of Ser. No. US 1989-428454, filed on 19 Oct 1989, now abandoned Which is a continuation in-part of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned Which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now utility
Granted
Elliott, George C. Expression of heterologous proteins in drosophila cells oblansen, Hanne Ranch, Hojbjerg, Denmark Van Der Straten-Ponthoz, Ariane Adrienne, Chicago, IL, United States Garry, Sean M. Eagle, Alissa M., Venetianer, Stephen A., Lentz, Edward T. LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the expression of heterologous genes, under the control of a Drosophila metallothionein promoter, inserted at high copy number into Drosophila melanogaster cells. Rosenberg, Martin, Royersford, PA, United States(4) SmithKline Beceham Corporation, Philadelphia, PA, Inted States (U.S. corporation) DATE KIND USPATFULL 1998:1646 USPATFULL NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: L5 ANSWER 32 OF 46 ACCESSION NUMBER: LEGAL REPRESENTATIVE: PATENT ASSIGNEE(S): PATENT INFORMATION: FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: NUMBER OF CLAIMS: EXEMPLARY CLAIM: DOCUMENT TYPE: INVENTOR(S):

Expression of heterologous proteins in Drosophila cells Johansen, Hanne Ranch, Hojbjerg, Denmark Van Der Straten-Ponthoz, Ariane Adrienne, Chicago, IL, Rosenberg, Martin, Royersford, PA, United States(4) SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation) 97:99166 USPATFULL United States USPATFULL ANSWER 33 OF 46 PATENT ASSIGNEE (S): ACCESSION NUMBER: INVENTOR (S):

US 5681133 19971028 US 1993-96016 1993077 (8) Continuation of Ser. No. US 1991-681222, filed on 5 Apr 1991, now abandoned which is a continuation-in-part of PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

KIND

NUMBER

Ser No. US 1988-278386, filed on 1 Dec 1988, now abandoned And Ser. No. US 1990-57453, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now abandoned

DOCUMENT TYPE:

Granted

Prouty, Rebecca E. Eagle, Alissa M., Lentz, Edward T., Venetianer, Stephen LEGAL REPRESENTATIVE: PRIMARY EXAMINER:

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells. LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The Dresent innoction

USPATFULL 97:59306 46 LS ANSWER 34 OF ACCESSION NUMBER:

Isolation and characterization of a novel chaperone USPATFULL protein

Cycle Frederic J., Bethesda, MD, United States Otterson, Gregory A., Columbia, MD, United States The United States of America as represented by the Destruent of Health and Human Services, Washington, DC, United States (U.S. government) PATENT ASSIGNEE (S) : INVENTOR (S):

DATE KIND NUMBER

19970708 US 5646249 US 1994-203

Granted Wax, Robert A. Lau, Kawai Knobbe, Martens, Olson & Bear 1994-203905 FILE SEGMENT:
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention relates to the identification and molecular characterization of the human and rat STCH chaperone protein including the corresponding gene sequence, gene fragments and protein fragments. The invention also relates antibodies to STCH and to assays to detect the presence of STCH genes, transcripts and protein in a sample.

USPATFULL 46 Q.

L5 ANSWER 35 OF ACCESSION NUMBER: TITLE:

97:18382 USPATFULL
Mortalin and methods for determining complementation group assignment of cancer cells
Pereira-Smith, Olivia M., Houston, TX, United States Wadhwa, Renu, Tsukuba, Japan
Baylor College of Medicine, Houston, TX, United States (U.S. corporation) PATENT ASSIGNEE(S): INVENTOR (S):

DATE KIND NUMBER

8 19970506 US 5627039
US 1994-214583
US 1994-214583
UDility
Granted
Scheiner, Toni R.
Fulbright & Jaworski L.L.P. APPLICATION INFO.:
DOCUMENT TYPE:
FILE SEGMENT:
PRIMARY EXAMINER:
LEGAL REPRESENTATIVE: PATENT INFORMATION:

6 1 6 <u>Drawing Figure(8); 4 Drawing Page(8)</u> NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

LINE COUNT:

1277

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The intracellular distribution of mortalin is used to determine the complementation group of tumor cells. Also disclosed are the gene sequences that encode mortalin and the amino acid sequence of the mortalin proteins.

USPATFULL L5 ANSWER 36 OF 46 ACCESSION NUMBER: TITLE:

97:29572 USPATFULL
Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney calls
Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
ARCH Development Corporation, Chicago, IL, United States States (U.S. corporation) PATENT ASSIGNEE(S):

INVENTOR(S):

6 Drawing Figure(s); 3 Drawing Page(s) 8 DATE Reeves, Julie E. Brinks Hofer Gilson & Lione KIND Nucker, Christine M. Reeves, Julie E. ASSISTANT EXAMINE:
Reeves, Julie E.
LEGAL REPRESENTATIVE:
Brinks Hofer Gilson
NUMBER OF CLAIMS:
SEREMPLARY CLAIM:
NUMBER OF DRAWINGS:
6 Drawing Figure(8);
LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An autocrine crystal adhesion inhibite US 5618917 US 1995-389005 Utility NUMBER PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER

An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by Kidney epithelial cells that blocks adhesion of calcium exalate monohydrate (COM) crystals to the Cell surfaces. Persons may be classified according to risk of developing Kidney stones, by measuring the amount of Call in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect epithelial cells is characterized.

USPATFULL ANSWER 37 OF 46 LS ANSWER 37 OF ACCESSION NUMBER: TITLE:

INVENTOR (S):

97:1357 USPATFULL

Recombinant BCG
O'Donnell, Michael A., Sudbury, MA, United States
Duda. Rosemary B., Carlisle, MA, United States
Dudolf, William C., Southborough, MA, United States
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
Beth Israel Hospital, Boston, MA, United States

Whitehead Institute For Biomedical Research, Cambridge, MA, United States (U.S. corporation) corporation)

PATENT ASSIGNEE(S):

US 593-9602 19970107 8)
US 1993-9602 19930722 (8)
Continuation-in-part of Ser. No. US 1991-711334, filed continuation-in-part of Ser. No. US 1989-367894, filed DATE KIND NUMBER RELATED APPLN. INFO.: PATENT INFORMATION: INFO.: APPLICATION

on 19 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-361944, filled on Signatuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-213089, filled on 22 Jul 1988, now abandoned And a continuation-in-part of Ser. No. US 1988-16390, filled on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filled on 3 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filled on 2 Mar 1987, now abandoned US 1987-20451, filled use a continuation-in-part of Ser. No. US 1987-20451, filled on 2 Mar 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filled use a cont

Vogel, Nancy T. Hamilton, Brook, Smith & Reynolds, P.C. FILE SEGNENT: CLAILLY
FILE SEAMENT: Granted
FILESAL REPRESENTATIVE: Hamilton, Brook, Smit
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIMS: 1
NUMBER OF DEALMINGS: 10
LINE COUNT: 1313
LINE COUNT: AMILABLE FOR THIS PATENT:
AB The present invention relates to recom

20 Drawing Figure(s); 10 Drawing Page(s)

The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired or a cytokine.

LS ANSWER 38 OF 46 ACCESSION NUMBER:

USPATFULL
96:113834 USPATFULL
Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
Stover, Charles K., Silver Spring, MD, United States MedImmune, Inc., Gaithersburg, MD, United States (U.S. INVENTOR(S): PATENT ASSIGNEE(S):

corporation)

60 Drawing Figure(s); 64 Drawing Page(s) 19961210 DATE KIND PRIMARY EXAMINES: Granted PRIMARY EXAMINES: Fleisher, Mindy ASSISTANT EXAMINES: Carter, Philip W. LEGAL REPRESENTATIVE: Olstein, Elliot M. NUMBER OF CLAINS: 1 INDER OF DRAWINGS: 60 Drawing Figure(s); LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB AN expression vector for avvecent. NUMBER Utility RELATED APPLN. 'INFO.: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

An expression vector for expressing a protein or polypeptide in a harterium, which comprises a first DNA sequence encoding at least a secretion signal of a lipoprotein, and a second DNA sequence encoding a protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. The bacterium expresses a fusion protein a lipoprotein or lipoprotein segment and the protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. Such expression vectors increase the immunogenicity of the protein or fragment thereof, or polypeptide or peptide by enabling the protein or fragment thereof, or polypeptide or peptide by enabling the protein or fragment thereof, or polypeptide or peptide to be expressed on the surface of the bacterium. Bacteria which may be transformed with the expression vector include mycobacteria such as BGG. The expression

vectors of the present invention may be employed in the formation of live bacterial vaccines against Lyme disease wherein the bacteria express a surface protein of Borrelia burgdorferi, the causative agent of Lyme disease.

LINE COURT.

CAS INDEXTING IS AVAILABLE FOR THIS PATENT.

CAS INDEXTING IS AVAILABLE FOR THIS PATENT.

AB Polynuclectide sequences, comprising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynuclectides can be contained within liposomes or the polynuclectides can be contained within interpretation proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents. US 5578303
US 1993-151052
US 1993-151052
US 1991-5148, filled on 29
Aug 1991, now abandoned which is a continuation-in-part
of Ser. No. US 1990-493127, filed on 14 Mar 1990, now US 5580859
US 1994-215405
US 1994-215405
US 1997-315405
Ser. No. US 1992-846827, filed on 6 Mar 1992, now abandoned which is a division of Ser. No. US 1990-49591, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned Cohen, Irun R., Rehovot, Israel
Elias, Dana, Rehovot, Israel
Markovits, Doron, Rehovot, Israel
Yeda Research and Development Co. Ltd., Rehovot, Israel
(non-U.S. corporation) 96:111449 USPATFULL
Delivery of exogenous DNA sequences in a mammal
Pelgner, Philip L., Rancho Santa Fe, CA, United States
Wolff, Jon A., Madison, WI, United States
Rodes, Gary H., Leucadia, CA, United States
Malone, Robert W., Chicago, IL, United States
Carson, Dennis A., Del Mar, CA, United States
Carson, Dennis A., Del Mar, CA, United States
VICAL Incorporated, San Diego, CA, United States corporation) Wisconsin Alumni Research Foundation, Dane, WI, United States (U.S. corporation) USPATFULL 96.108677 USPATFULL Diagnosis and treatment of insulin dependent diabetes 10 Drawing Figure(s); 9 Drawing Page(s) DATE DATE Stone, Jacqueline M. Crouch, Deborah Knobbe, Martens, Olson & Bear KIND KIND NUMBER NUMBER Utility Granted mellitus USPATFULL APPLICATION INFO.: RELATED APPLN. INFO.: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: L5 ANSWER 40 OF 46 ACCESSION NUMBER: APPLICATION INFO.: RELATED APPLN. INFO.: L5 ANSWER 39 OF 46 ACCESSION NUMBER: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE(S): PATENT ASSIGNEE(S): PATENT INFORMATION: PATENT INFORMATION: NUMBER OF CLAIMS: PRIMARY EXAMINER: DOCUMENT IYPE: INVENTOR (S): INVENTOR(S):

abandoned which is a continuation-in-part of Ser. No. US 1989-37149, filled on 26 Jun 1989, now patented, Pat. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filed on 14 Mar 1989, now 11 Drawing Figure(s); 10 Drawing Page(s) Cunningham, Thomas M. LEGAL REPRESENTATIVE: Browdy and Neimark NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure (e LINE COUNT: 1922
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB A 65 KD heat shock protein. abandoned Utility Granted FILE SEGMENT: PRIMARY EXAMINER:

A 65 MD heat shock protein, proteins cross-reactive therewith, antibodies therefor or T cells specific thereto can be used for detecting in humans the existence or T cells specific thereto can be used for detecting a process leading to insulin dependent diabetes mellitus. Antibodies to a process leading to insulin dependent diabetes mellitus. Antibodies to hisp55 anb be used to detect the hisp55 molecule in blood or winne. The hisp55 molecule in blood or winne. The hisp56 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, and be used for the prevention or treatment of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of

USPATFULL
96:77659 USPATFULL
Expression of heterologous proteins in Drosophila cells
Johanese, Hanne R., Holbjerg, Denmark
Van Der Straten-Ponthoz, Ariane A., Chicago, IL, United L5 ANSWER 41 OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S):

Rosenberg, Martin, Royersford, PA, United States (4) SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation) States PATENT ASSIGNEE(S):

DATE KIND NUMBER

US 5550043
US 1995-43178
US 1996-43178
US 1996-43178
US 1996-574563, filed on 10 Dec 1988, now abandoned And Ser. No. US 1990-574563, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-428454, filed on 30 Oct 1989 which is a continuation of Ser. No. US 1987-47736, filed on 8 May APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

Elliott, George C. Sutton, Jeffrey A., Jervis, Herbert H., Lentz, Edward Utility Granted DOCUMENT TYPE: SEGMENT

LINE COUNT:
1153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The DEFERENT FINANCE OF THE PATENT. PRIMARY EXAMINER: LEGAL REPRESENTATIVE:

The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.

96:55678 USPATFULL In vitro activation of cytotoxic t-cells using insect cells expressing human class I MHC and USPATFULL ANSWER 42 OF 46 L5 ANSWER 42 OF ACCESSION NUMBER: TITLE:

	.beta.2-microglobulin
INVENTOR(S):	Peterson, Per A., La Jolla, CA, United States
	Jackson, Michael, Del Mar, CA, United States
	Langlade-Demoyen, Pierre, Del Mar, CA, United States
PATENT ASSIGNEE(S):	Scripps Research Institute, La Jolla, CA, United State
	(U.S. corporation)
	NUMBER KIND DATE
PATENT INFORMATION:	US 5529921 19960625
APPLICATION INFO.:	US 1994-209797 19940310 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-841662, filed on 19 Feb
	1992, now patented, Pat. No. US 5314813
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Adams, Donald E.
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT:	3968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	BLE FOR THIS PATENT.
An The present into	The present investion relates to a retional elector means of production

ģ

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CDB cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human. beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same. B

ĭ, McGuize, deceased, William L., late of San Antonio, Tr United States by John W. Robb, legal representative Clark, Garry M., San Antonio, TX, United States Chamess, Gary C., San Antonio, TX, United States Tandon, Atul K., San Ramon, TX, United States Fuqua, Suzanne A., San Antonio, TX, United States Board of Regents. The University of Texas System, Austin, TX, United States (U.S. corporation) 95:80215 USPATFULL Heat shock/stress response proteins and prognosis in cancer LS ANSWER 43 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): INVENTOR (S)

PCT 371 date PCT 102(e) date 5 19921125 19910412 19921125 19921125 19950905 DATE US 5447843 WO 9116632 US 1992-949630 WO 1991-US2536 NUMBER PATENT INFORMATION: APPLICATION INFO.:

filed 20100223 Continuation-in-part of Ser. No. US 1990-509377, 3 0n 12 Apr 1990, now patented, Pat. No. US 5188964 Utility DISCLAIMER DATE: RELATED APPLN. INFO.: DOCUMENT TYPE:

Scheiner, Toni R. Arnold, White & Durkee

Granted

PRIMARY EXAMINER:

Drawing Figure(s); 6 Drawing Page(s) EXEMPLARY CLAIM: 15
NUMBER OF DRAWINGS: 14 Drawing Figure (
1371
CAS INDEXING IS AVAILABLE FOR THIS PATENT. LEGAL REPRESENTATIVE: NUMBER OF CLAIMS:

The invention relates to a method of predicting disease-free survival in cancer patients by relating the number and amount of stress response proteins in cancer tissue to the probability of tumor recurrence.

Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins. Appl. hsp90, hsp90, hsp27, and glucose regulated protein grp94. Specific levels of the stress response proteins relative to an internal armadrad are identified, above which the probability of tumor recurrence is highly significant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay. B

Peterson, Per A., LaJolla, CA, United States
Jackson, Michael, Del Mar, CA, United States
Langlade-Demoyen, Pierre, Del Mar, CA, United States
Scripps Research Institute, LaJolla, CA, United States Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines 94:44555 USPATFULL (U.S. corporation) ANSWER 44 OF 46 USPATFULL PATENT ASSIGNEE(S): ACCESSION NUMBER: TITLE: INVENTOR (S): ន

Hill, Jr., Robert J. Allen, Marianne P. Logan, April C., Liebeschuetz, Joe, Smith, William M. 5 19940524 DATE KIND US 5314813 US 1992-841662 NUMBER Utility Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: PATENT INFORMATION:

24 Drawing Figure(s); 19 Drawing Page(s) CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a LINE COUNT:

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human. beta. 2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

93:100493 USPATFULL
Insect specific paralytic neurotoxin genes for use insect specific paralytic neurotoxin genes for use in 10.00-gaical insect control: methods and compositions Tomalski, Michael D., Athens, GA, United States Miller. Lois K., Athens, GA, United States Millersity of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation) USPATFULL L5 ANSWER 45 OF ACCESSION NUMBER: ANSWER 45 OF INVENTOR (S):

KIND NUMBER

PATENT ASSIGNEE(S):

0 19901004 Greenlee and Winner Furman, Keith C. US 1990-593657 US 1990-593657 Utility Granted Wax, Robert A. ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: PRIMARY EXAMINER:

NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

1 9 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT: 2085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Genes encoding insect-specific paralytic neurotoxins, particularly those of insect-parasitic mites, including Pyemotes, are described.

Of insect-parasitic mites, including Pyemotes, are described.

Becombinant DNA molecules in which the neurotoxin coding sequences are placed under the control of heterologous promoters are also described. Such molecules are useful for the development of biological insect control agents which produce insect-toxic levels of the neurotoxin. Specifically described are genetically altered baculoviruses which produce insect-specific paralytic neurotoxins and which display improved toxic effect on insects. Insect-toxic compositions are also provided. Described in the control using these neurotoxin genes, methods for production of neurotoxins in cells, and methods of production of insect control agents are described.

Method and Kit for the prognostication of breast cancer batied and Kit for the prognostication of breast cancer partient via heat shock/stress protein determination McGuire, William L., San Antonio, TX, United States Tandon, Atul K., San Antonio, TX, United States Clark, Gary M., San Antonio, TX, United States Chamness, Gary C., San Antonio, TX, United States Board of Regents, The University of Texas System, Austin, TX, United States 5 19900412 19930223 Housel, James C. Chan, William Arnold, White & Durkee US 5188964 US 1990-509377 Utility NUMBER USPATFULL Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: ANSWER 46 OF 46 PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: L5 ANSWER 46 OF ACCESSION NUMBER: TITLE: PRIMARY EXAMINER INVENTOR (S):

14 Drawing Figure(s); 6 Drawing Page(s) EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 14 Drawing Figure (ELINE COUNT: 1495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of

The invention relates to a method of predicting disease-free survival cancer patients by relating the number and amount of stress response proteins in the cancer tissue to the probability of tumor recurrence. Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins, bsp70, hsp90, hsp27, and glucose regulated protein grp94. Specific levels of the stress response protein grp94 which the probability of tumor recurrence is highly significant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay.

=> d his

(FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

'USPATFULL' ENTERED AT 07:32:03 ON 11 S 820 S HSP70 OR HEAT SHOCK PROTEIN 70 340 S L1 AND ADUVANT 340 DUP REM L2 (0 DUPLICATES REMOVED) 340 S L3 FILE 4224

L5 46 S L3 NOT PY=>1999		NCLS, EXF, REP, R
s > 12 and pharmaceutic	FPBIB	PARN, SUMM, DRWD, PI, TI, IN, INA,
523 PHARMACEUTIC	FHITSTR	
180	FPG	its structure dia FP plus PAGE.DRAW
L6 0 L2 AND PHARMACEUTIC	GI	
î	HITRN	
-> s 12 and pharmaceutical?	HITSTR	HIT RN, its text
144	IABS	ABS, indented wit
L/ 266 LZ AND FHARMACEUTICAL?	IALL	ALL, indented with
=> \$ 17 and cancer	IBIB	
SZIZB CANCERS 15572 CANCERS	IBIB.EX	IBIB for original IBIB plus PAGE.DR
54070 CANCER OF CANCERS	IMAX	
L8 210 L7 AND CANCER	IND	
=> s 18 and administer?	ISTD	EXF, ARTU, OS, CC STD, indented with
14288 ADMINISTER? L9 207 LB AND ADMINISTER?	KWIC	All
;	vui.	RLI, PRAI, DT, FS
-> S 19 and Treat? 787080 TREAT?		DRWN, AB, GOVI, P.
L10 207 L9 AND TREAT?		EXF, ARTU OS, CC,
=> s 110 not pye>1999	MAX.EX	
816008 PY=>1999		
6676-X-1 TO NOT 5.7 TTT	SCAN	DT, FS, LN.CNT AN, TI, NCL, NCLM
-> d 1-14 ibib and ab 'AND' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'		without answer nu
mb. 6.11	STD	AN, TI, IN, INA,
ine collowing are valid formats:		DT, FS, LN.CNT, I
The default display format is STD.	STD.EX	STD for original
ABS AB	TRIAL	AN, TI, INCL, INC
		221, 121
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL, DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,	ENTER DISPLA	ENTER DISPLAY FORMAT (STD):end
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS, EXF. ARTU	=> d his	
PAGE. DRAW	(FILE	(FILE 'HOME' ENTERED AT 0
ı	n. 3113	USPATEUL, ENTERED
BIBS BIB for original and latest publication		820 S HSP70 OR HEA
		340 S L1 AND ADJUV. 340 DUP REM 1,2 (0
line as DISPLAY, e.g., D		340 S L3
	1.5 1.6	46 S L3 NOT PY=>1 0 S L2 AND PHARM
DALL ALL, delimited for post-processing FP DI TI IN IND DE DAL DAT BATEDM OFF AT DIT		266 S L2 AND PHARM
PRAI, IC, ICM, ICS, INCLM, INCLM, INCLM, MCI,		ດທ
	L10	207 S L9 AND TREAT
FP.EX FP for original and latest publication FPALL PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,	=> d 111 1-14 ibib ab	4 ibib ab
RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,	1 1 4 4 5	25 2174

```
PUCIS, EEF, PERS, REAR, PERS, LEAN, PERP, CLAN, DRAN, ARP,
PARX, SIRW, DRAN, DETD CLA, PARY, PRESM, DCD, AI,
PLIT, TRI, THAN, DETD CLA, PARY, PRESM, DCD, AI,
PLIT, PRAI, REP, REAR, EARA, PARY, PRESM, DCA, INGEX name, and
ISE CHITCHER AIR SECTION OF THE CLAN CLANK, DRAN
PHITSTR. HITT RN, ISE TEAT MODIFICATION, ISE CA INGEX name, and
HITTAN, AIL IGERS CONCELLING THE CEAT MODIFICATION, ISE CA INGEX name, and
HITTAN, AIL IGERS CONCELLING THE CEAT AIR SECTION OF THE CASE, INDERCED AIR SECTION OF THE CASE OF THE CA
```

ATFOLL	1998:151078 USPATFULL	Vertebrate embryonic pattern-inducing proteins, and	uses related thereto	Ingham, Philip W., Summertown, England	McMahon, Andrew P., Lexington, MA, United States	Tabin, Clifford J., Cambridge, MA, United States	President and Fellows of Harvard College, Cambridge,	MA, United States (U.S. corporation)	
USPA	7	>	Þ	H	Σ	H	Д	Σ	
LII ANSWER 1 OF 14 USPATFULL	ACCESSION NUMBER:	TITLE:		INVENTOR(S):			PATENT ASSIGNEE(S):		

KIND

PATENT INFORMATION:	US 5844079 19981201
APPLICATION INFO.:	US 1994-356060 19941214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-176427, filed
	on 30 Dec 1993
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Walsh, Stephen
ASSISTANT EXAMINER:	Sorensen, Kenneth H.
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Arnold, Beth E.Foley, Hoad & Eliot
	LLP
NUMBER OF CLAIMS:	41
EXEMPLARY CLAIM:	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 21 Drawing Page(s)
musco una	

NUMBER OF CLAAR...

REEMPLARY CLAIM:

NUMBER OF DRAWINGS:

2 Drawing Figure(s); 21 LL.

NUMBER OF DRAWINGS:

7618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

PATENT INFORMATION:	US 5837251	19981117	
APPLICATION INFO.:	US 1995-527391	19950913 (8)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Bansal, Gee Tha D.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1,8,16		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 8 Drawing Page(s)	Drawing Page(s)	
LINE COUNT:	2361		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	BLE FOR THIS PATENT.		

B

US 1994-184009
US 1994-184009
US 1994-184009
Continuation-in-part of Ser. No. US 1993-7115, filed on continuation-in-part of Ser. No. US 1992-847951, filed on Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a

DATE

KIND

NUMBER

PATENT ASSIGNEE(S):

INVENTOR(S):

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

1998:138427 USPATFULL
Canarypox virus expressing cytokine and/or
tumor-associated antigen DNA sequence
Paoletti, Enzo, Delmar, NY, United States
Tartaglia, James, Schenectady, NY, United States
Cox, William I., Troy, NY, United States
Virogenetics Corporation, Troy, NY, United States
corporation)

USPATFULL

L11 ANSWER 4 OF 14 ACCESSION NUMBER: TITLE:

DATE

KIND

PEXING IS AVAILABLE FOR THIS PATENT.

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metestatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprise administering a composition

consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule, "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens, famunogens (i.e., with which the hsps are not complexed in vivo) or antigens/immunogens (i.e., with which the hsps are not thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10.600 micrograms for hsp9, and 10.600 micrograms for hsp9, and 10.600 micrograms for hsp9, and 10.600 micrograms for provides a method for measuring tumor rejection in vivo in an individual preferably a human, comprising measuring the generation by the individual of MFC class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide

USPATFULL 1998:13662 USPATFULL POLYMUSTER ENCODING a cofactor A-like protein Polymusterides encoding a cofactor A-like protein Hillman, Jennifer L., San Jose, CA, United States Goll, Surya K., Sunnyale, CA, United States Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)	NUMBER KIND DATE	782		9 1 3 Drawing Figure(s); 3 Drawing Page(s) 1933	CAS INDEXING IS AVAILABLE FOR THIS PATENT.  AB The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR.
L11 ANSWER 3 OF 14 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):		PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT:	PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:	NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: LINE COUNT:	CAS INDEXING IS AVAI  AB The present i and polynucle provides expr antagonists. disorders ass

continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned, said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 7115 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-808080, filed on 7 Jan 1991, now abandoned, said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1992-478779, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320471, filed on 8 Mar 1989, now patented, Pet. No. US 5155020

FILE SEGMENT: PRIMARY EXAMINER:

Crouch, Deborah Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J. LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS: 5
EXEMPLEARY CLAIM: 5
EXEMPLEARY CLAIM: 46
INUMBER OF DEAWINGS: 46
INDECOUNT: 8834
CAS INDEXING S AVAILABLE FOR THIS PATENT.
AB Attenueted vaccinia or canarybox rec

46 Drawing Figure(s); 33 Drawing Page(s)

Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytckine and/or a tunor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses can be NYVAC or ALVAC recombinant viruses; The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphopyortein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IRN.gamma.; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for canoer therapy.

USPATFULL ANSWER 5 OF 14

LII ANSWER 5 OF 1 ACCESSION NUMBER: TITLE:

1998:134628 USPATFULL Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. INVENTOR(S): PATENT ASSIGNEE(S):

corporation)

NUMBER

DATE

KIND

PATENT INFORMATION: US 5830464

DOCUMENT TYPE: Utility
TELE SEGMENT:
FILE SEGMENT:
FRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: Sanders, David
ASSISTANT EXAMINER: Sanders, David
ASSISTANT EXAMINER: SanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & Edmonds LLP
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & LEGAL REPRESENTATIVE
LEGAL REPRESENTATIVE: Dennie REPRESENTATIVE
LEGAL REPRESENTATIVE
LEGAL

refers to the peptides with which the haps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the haps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hap70, 5 to 49 micrograms for hap90, and 0.1 to 9.0 micrograms for complexes comprising for gp96. In another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising hap70, 50 to 5000 micrograms for hap90, and 10 to 600 micrograms for gp96.

USPATFULL ANSWER 6 OF 14

Heat shock-like protein
Hallman, Jennifer L., San Jose, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
Incyce Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation) ACCESSION NUMBER: INVENTOR (S):

PATENT ASSIGNEE(S):

DATE KIND NUMBER

5 Drawing Figure(s); 4 Drawing Page(s) (8) 19980929 Wax, Robert A. Bugalsky, Gabriele E. Billings, Lucy J. ASSISTANT EXAMINER: Bugalsky, Gabriele E.
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAINS: 8
NUMBER OF CLAINS: 8
NUMBER OF CLAINS: 5
Drawing Figure(s);
LINE COUNT: 1943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a construction. US 1997-846134 Utility Granted PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: PRIMARY EXAMINER FILE SEGMENT:

The present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.

USPATFULL

L11 ANSWER 7 OF 14 ACCESSION NUMBER:

Inhibitors of IMPDH enzyme
Armistead, David M. Maynard, MA, United States
Badia, Michael C., Bedford, MA, United States
Benis, Guy W., Arlington, MA, United States
Benis, Randy S., Allston, MA, United States
Bethiel, Randy S., Allston, MA, United States
Frank, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Matertown, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
Vertex Pharmaceuticals Incorporated, Cambridge, MA,
United States (U.S. corporation) INVENTOR (S):

PATENT ASSIGNEE(S):

8 DATE US 5807876 US 1996-636361 NUMBER Granted PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT:

Shah, Mukund J. Kifle, Bruck Fish & Neave, Haley, Jr., James F., Govindaswamy, N. PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1494

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmacoutical compositions comprising these compounds. The compounds and pharmacoutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, well suited for inhibiting the activity and consequently, well suited for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

111 ANSWER 8 OF 14 USPATFULL

ACCESSION NUMBER:

Human protein disulfide isomerase

DATE

KIND

NUMBER

ACCESSION NUMBER: 1998:101540 USPATFULL
TITLE: Human protein disulfide isomerase
INVENTOR(S): Braxton, Scott Michael, San Mateco, CA, United States
Murry, Lynn E., Pórtola Valley, CA, United States
PATENT ASSIGNEE(S): INCYE Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5798249

RELATED APPLICATION INFO.: US 1996-650275

BOCUMENT TYPE: Utility

PRIMARY EXAMINER: Wax, Nobert A.

PRIMARY EXAMINER: Wax, Nobert A.

PRIMARY EXAMINER: Saidha, Tekchand

FEASISTERMENT EXAMINER: Saidha, Tekchand

DOCUMENT TYPE: OIL 12 may 1390
PILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTNAT EXAMINER: Saidha. Texchand
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2291
LINE COUNT: ANAILABLE FOR THIS PATENT.
AB The present invention provides a polynucleotide (adih) the

The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in planmacentical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in planmacentical compositions for treatment of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of pdih, or anti-PDIH antibodies which specifically bind to the polypeptide, PDIH.

L11 ANSWER 9 OF 14 USPATFULL ACCESSION NUMBER: 1998:92162 USPATFULL

ACCESSION NUMBER: 1998:921b2 USFAIRULL
ITLE: Vertebrate embryonic pattern-inducing proteins and uses related thereto Induan, England Indian, Philip W., Summertown, England

INVENTOR(S): Ingland, Philip W., Summertown, England McMahon, Philip W., Lexington, MA, United States Tabin, Cliffcond J., Cambridge, MA, United States President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

EXEMPLARY CLAIM:

I Drawing Figure(s); 15 Drawing Page(s)

NUMBER OF DRAWINGS:

12 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in Deltex proteins
Attavania-Taskonas, Spyridon, Hamden, CT, United States
Busseau, Isabelle, Bures-Sur-Yvette, France
Diederich, Robert J., New Haven, CT, United States 1998:88652 USPATFULL
Therapeutic and diagnostic methods and compositions
based on north proteins and nucleic acids
Artavanis-Tsakonas, Spyridon, Hamden, CT, United States
Febron, Richard Grant, Durham, NC, United States
Zagouras, Panayiotis, New Haven, CT, United States
Blaumueller, Christine Marie, New Haven, CT, United The present invention relates to diagnostic methods and compositions for detection of malignancy or nervous system disorders based on the level of Notch proteins or nucleic acids. Therapeutic methods and methods of inhibiting Notch expression are also provided. Walsh, Stephen Sorensen, Kenneth A. Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP US 5786158
US 1993-83590
US 1993-83590
US 1993-83590
US 1993-83590
US 1992-955012, filed
On 30 Sep 1992, now abandoned And a
continuation-in-part of Ser. No. US 1992-879038, filed
On 30 Apr 1992, now abandoned
Utility
Granted States Yale University, New Haven, CT, United States (U.S. Typozation) 70 Drawing Figure(s); 68 Drawing Page(s) 8 19980804 DATE KIND USPATFULL 1998:51728 USPATFULL Scheiner, Toni R. Pennie & Edmonds LLP 9 LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to di US 5789543 US 1993-176427 Utility Granted NUMBER USPATFULL vitro and in vivo. PRIMARY EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: L11 ANSWER 10 OF 14 t ACCESSION NUMBER: TITLE: APPLICATION INFO.: RELATED APPLN. INFO.: LEGAL REPRESENTATIVE: L11 ANSWER 11 OF 14 ACCESSION NUMBER: INFORMATION: PATENT ASSIGNEE(S): PATENT INFORMATION: PRIMARY EXAMINER: ASSISTANT EXAMINER: APPLICATION INFO.: NUMBER OF CLAIMS: DOCUMENT TYPE: DOCUMENT TYPE: FILE SEGMENT: INVENTOR (S): INVENTOR (S):

Xu, Tian, Guilford, CT, United States Macsuno, Kenji, New Haven, CT, United States Tate University, New Haven, CT, United States (U.S. corporation) PATENT ASSIGNEE(S):

	NUMBER	KIND DATE			
			;		
PATENT INFORMATION:	US 5750652	19980512	12		
APPLICATION INFO.:	US 1994-185432	19940121	21 (8)		
DOCUMENT TYPE:	Utility				
FILE SEGMENT:	Granted				
PRIMARY EXAMINER:	Walsh, Stephen				
ASSISTANT EXAMINER:	Sorensen, Kenneth A.				
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP				
NUMBER OF CLAIMS:	27				
EXEMPLARY CLAIM:	1				
NUMBER OF DRAWINGS:	58 Drawing Figure(s): 40 Drawing Page(s)	; 40 Drawi	ng Page	(S	
LINE COUNT:	4194		)		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	BLE FOR THIS PATENT.				
AB The present inve	The present invention relates to amino acid sequences of the encode	o acid seq	nences	of the	encode

BANDIABLE FOR THIS PATENT.

The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other deltex protein. The invention further relates to fragments and other the invention relates to deltex protein. In specific embodiments, the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gin-rich clusters, SH3 binding domains, domains which mediate binding to Notch or to a Notch derivative containing Notch cdc10/SM16/ankyrin (\*ANK") any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

against cancer
Strusteva, Pramod K., Riverdale, NY, United States
Strusteva, Pramod K., Riverdale, NY, United States
Mount Sinal School of Medicine Of The City University
of New York, New York, NY, United States (U.S.
corporation) USPATFULL 1998:51204 USPATFULL Immunotherapeutic stress protein-peptide complexes L11 ANSWER 12 OF 14 ACCESSION NUMBER: INVENTOR(S): PATENT ASSIGNEE(S): TITLE:

DATE

KIND

NUMBER

US 575019 US 1994-131892 US 1994-131892 Ocutinuation-in-part of Ser. No. US 1994-180685, filed on 13 Jan 1994 Utility Granted Peisee, Lila Bansal, Geetha P. PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE:

NUMBER OF CIAIMS:

1.2

ILVE COUNT:

AB DISclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steeps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexe having particular utility in the practice of the instant invention include the Hap70

-peptide, Hsp90-peptide and gp96-peptide complexes.

Stone, Jacqueline M. Crouch, Deborah Knobbe, Martens, Olson & Bear

FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE:

EXEMPLARY CLAIM:

1 Drawing Figure(s); 9 Drawing Page(s)

2572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB POLYNUCIPECTIES sequences, compirising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide.

The polynuciectides can be contained within liposomes or the polynuciectides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.

The state of the s

and the same of th